Question 1

What did SYNERGY-NASH actually find?

Accepted Answer

On its primary endpoint — Liver inflammation resolved on biopsy at 52 weeks, with scarring no worse — the treatment arm recorded 15 mg: 62% (95% CI 47-77); 10 mg: 56% (95% CI 41-71); 5 mg: 44% (95% CI 29-59) against Placebo: 10% (95% CI 0-21) for the comparator. All three tirzepatide doses significantly superior to placebo (P<0.001 for each). The endpoint is unusually hard to pass: two liver biopsies a year apart, scored by pathologists who did not know who got what. This is the standard regulators ask for, not a scan or a blood test, and it is why a 190-person trial carries weight it otherwise would not. The three doses lined up in order.

Question 2

How large was SYNERGY-NASH, and how long did it run?

Accepted Answer

190 participants, over 52 weeks of treatment, with a liver biopsy at the start and another at the end to score the main result. It was a Phase 2 trial, finished; headline results published June 2024. Registered as NCT04166773, which you can look up yourself rather than taking anyone's summary for it.

Question 3

Who was studied in SYNERGY-NASH?

Accepted Answer

Adults 18 to 80 with a BMI between 27 and 50, weight stable for at least three months, and MASH confirmed by biopsy with stage F2 or F3 scarring (significant, but short of cirrhosis). People with type 2 diabetes could join if their HbA1c was 9.5% or below, and about 58% had it. Exclusions were extensive: cirrhosis, any other liver disease, prior pancreatitis, substantially reduced kidney function, a family history of medullary thyroid cancer, a raised calcitonin, a recent cardiac event, and any cancer within five years. Average weight around 95 kg at a BMI near 36, about 57% women. ⚠ A trial result describes the population it was measured in. If you differ from it materially — in age, in baseline weight, in whether you have diabetes — the number is context rather than a prediction.

Question 4

What side effects were reported in SYNERGY-NASH?

Accepted Answer

The most commonly reported were nausea (5 mg: 36%; 10 mg: 34%; 15 mg: 44% against 13% on comparator), diarrhea (5 mg: 32%; 10 mg: 36%; 15 mg: 27% against 23% on comparator), constipation (5 mg: 23%; 10 mg: 19%; 15 mg: 15% against 6% on comparator). Clustered while the dose was rising and highest at the top dose, the same pattern seen in the weight and diabetes trials. Every rate in this table except stopping the drug is per the trial's ClinicalTrials.gov results, which count events up to week 56 in about 47 or 48 people per arm. Rates come from this trial's population under its own dose-escalation schedule; a faster or slower titration changes what people experience.

Question 5

What else did SYNERGY-NASH measure?

Accepted Answer

Secondary endpoints included liver scarring actually improved by at least one stage, without the inflammation getting worse (15 mg: 51% (95% CI 35-66); 10 mg: 51% (95% CI 35-67); 5 mg: 55% (95% CI 39-71) against Placebo: 30% (95% CI 15-44)); how much body weight came off (15 mg: -15.6%; 10 mg: -13.3%; 5 mg: -10.7% against -2.3%); the combined liver damage score, adding up fat, inflammation and cell swelling (15 mg: -3.0; 10 mg: -3.0; 5 mg: -2.6 against -1.0). ⚠ Secondary endpoints are weaker evidence than the primary one — a trial is powered for its primary outcome, and the rest are read as supporting rather than as findings in their own right.

Question 6

Does SYNERGY-NASH apply to compounded tirzepatide?

Accepted Answer

No, and this matters because the number gets used that way. SYNERGY-NASH tested Tirzepatide — the FDA-approved product, made by its manufacturer under Good Manufacturing Practice, at the doses and schedule the protocol specified. A compounded preparation of tirzepatide is a different product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and its concentration is set by whichever pharmacy filled it. ⛔ A seller quoting this trial's result beside a compounded price is quoting evidence that was generated on something they are not selling. That is not the same as saying compounded tirzepatide does not work — it is saying nobody measured it here.

Question 7

Does SYNERGY-NASH mean this drug will work for me?

Accepted Answer

It cannot tell you that. A trial reports an average across a defined population under a fixed protocol, with monitoring and adherence support most people do not get. It is the best evidence available and it is still a distribution rather than a promise — some participants lost far more than the mean and some lost nothing. What it is genuinely good for is comparing options against each other, which is what the rest of this section is for.

Endpoint	Treatment	Comparator	Difference
Liver scarring actually improved by at least one stage, without the inflammation getting worse This is the more demanding of the two regulatory pillars (reversing damage rather than halting it), and roughly half the treated participants managed it against 30% on placebo. The doses did not line up here: 5 mg did as well as 15 mg, which hints that the scarring benefit tops out earlier than the inflammation benefit. That is a hypothesis from 190 people, not a finding.	15 mg: 51% (95% CI 35-66); 10 mg: 51% (95% CI 35-67); 5 mg: 55% (95% CI 39-71)	Placebo: 30% (95% CI 15-44)	Differences vs placebo: 25 (95% CI 5 to 46), 22 (95% CI 1 to 42) and 21 (95% CI 1 to 42) percentage points at 5, 10 and 15 mg
How much body weight came off In line with what this drug produces in weight trials at the same doses, which sets up the question of whether the liver result is anything more than the weight result.	15 mg: -15.6%; 10 mg: -13.3%; 5 mg: -10.7%	-2.3%	Placebo-subtracted: -13.3 (15 mg), -11.0 (10 mg), -8.4 (5 mg) percentage points
The combined liver damage score, adding up fat, inflammation and cell swelling Down 3 points on the higher doses against 1 on placebo, on a scale running 0 to 8. This score is the underlying arithmetic that produces the headline result.	15 mg: -3.0; 10 mg: -3.0; 5 mg: -2.6	-1.0	Placebo-subtracted reductions of 1.6-2.0 points; all three doses significantly different from placebo
How much fat left the liver, measured by MRI Down 59% at the top dose against 10% on placebo. A 30% reduction is generally enough to predict a biopsy response, so this comfortably clears it, and unlike a biopsy, it is a measurement someone could get repeated.	15 mg: -59%; 10 mg: -52%; 5 mg: -43%	-10%	All three doses significantly different from placebo
ALT, the liver enzyme most commonly tested Down substantially on every dose. Useful as corroboration but not sufficient on its own. Enzymes can normalize while disease persists, which is why regulators insist on tissue.	15 mg: -28 U/L; 10 mg: -24 U/L; 5 mg: -28 U/L	-10 U/L	Placebo-subtracted reductions of 14-18 U/L across tirzepatide doses
AST, the other routinely tested liver enzyme Down roughly twice as much as placebo, moving with ALT.	15 mg: -16 U/L; 10 mg: -14 U/L; 5 mg: -17 U/L	-7 U/L	Placebo-subtracted reductions of 7-10 U/L across tirzepatide doses
Three-month average blood sugar, in those who had diabetes Down about 1.6 points at the higher doses, matching what this drug does in dedicated diabetes trials. Those without diabetes moved about 0.4 points.	15 mg: -1.6%; 10 mg: -1.6%; 5 mg: -1.3%	-0.3%	Placebo-subtracted reductions of 1.0-1.3 percentage points in the T2DM subgroup
Liver stiffness measured by a non-invasive scan Improved on every dose. It matters because it agrees with the biopsy result using a completely different method, and two independent measures pointing the same way are much harder to explain away than one.	15 mg: -3.7 kPa; 10 mg: -3.1 kPa; 5 mg: -2.5 kPa	-0.5 kPa	All three tirzepatide doses produced larger reductions in liver stiffness than placebo

Event	Treatment rate	Comparator rate
Nausea Clustered while the dose was rising and highest at the top dose, the same pattern seen in the weight and diabetes trials. Every rate in this table except stopping the drug is per the trial's ClinicalTrials.gov results, which count events up to week 56 in about 47 or 48 people per arm.	5 mg: 36%; 10 mg: 34%; 15 mg: 44%	13%
Diarrhea Higher than placebo without tracking the dose closely.	5 mg: 32%; 10 mg: 36%; 15 mg: 27%	23%
Constipation Two to four times the placebo rate and highest at the lowest dose, a reminder that small trials produce noisy safety numbers.	5 mg: 23%; 10 mg: 19%; 15 mg: 15%	6%
Vomiting Highest at the top dose, against a single case on placebo.	5 mg: 6%; 10 mg: 6%; 15 mg: 15%	2%
Loss of appetite Recorded as a side effect, though it is how the drug works.	5 mg: 19%; 10 mg: 21%; 15 mg: 23%	2%
COVID-19 Listed because the trial ran from 2020 to 2023. It is background noise from the pandemic, not a drug effect, and a good illustration of why a raw adverse-event list needs reading rather than counting.	5 mg: 11%; 10 mg: 13%; 15 mg: 19%	8%
Stopped the drug over a side effect Only 3 to 6%, notably lower than this drug's weight and diabetes trials report. With 190 participants that may be chance rather than an easier experience.	5 mg: 3%; 10 mg: 6%; 15 mg: 4%	0%
Serious adverse events of any kind Uncommon in every arm, with none at all at the top dose and no pattern by dose, and specifically no sign of livers decompensating, which is the thing you would most want ruled out when treating liver disease.	5 mg: 11%; 10 mg: 9%; 15 mg: 0%	6%
Pancreatitis reported as an adverse event One nonserious case at the lowest dose and none elsewhere, too few to read anything into.	5 mg: 1 case; 10 mg: none; 15 mg: none	None

SYNERGY-NASH: Tirzepatide and Liver Disease

Primary endpoint

Secondary endpoints

Adverse events

Subgroup analyses

Clinical significance

Who sells tirzepatide, and for how much

Frequently Asked Questions

References